Snapshot

The Structure and Organization of Dossier for Orphan Drugs pathway has been developed by the of Mexico.

This pathway can be used where Product must comply with a prevalence of 5 per 10000.

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

Target time assessment is Not specified.